Pharmaceutical company AstraZeneca has signed a deal with SciLifeLab, a university consortium, to give researchers access to its small molecule compound library.
The aim of the collaboration is to help researchers identify novel protein targets aligned to unmet medical needs, according to SciLifeLab. Projects are expected to focus on so-called phenotypic assays, which have the ability to be used together with cells derived from patients.
The AstraZeneca library has about 14,000 compounds targeting more than 1,700 human proteins.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.